VivoSeq
Oncology

Metastatic Colorectal Cancer (CRC)

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Metastatic Colorectal Cancer (CRC) is an early-stage landscape with 0 programs across 1 company. The most active players are Summit Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Summit Therapeutics

2 programs

Phase 3

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer
Recruiting·SSummit Therapeutics·Phase 3·NCT07228832·600 enrolled
A Multicenter, Observational Clinical Study Evaluating the Application of Multi-Omics Tumor-agnostic Technology for Localizing Postoperative Local Recurrence and Distant Metastasis in Colorectal Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT07685236·586 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)